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SHP2 acts both upstream and downstream
of multiple receptor tyrosine kinases to
promote basal-like and triple-negative
breast cancer
Fatimah Matalkah1, Elisha Martin1, Hua Zhao1 and Yehenew M. Agazie1,2*

Abstract
Introduction: Dysregulated receptor tyrosine kinase (RTK) signaling is a common occurrence in basal-like and
triple-negative breast cancer (BTBC). As a result, RTK-targeting therapies have been initiated but proved difficult,
mainly owing to the multiplicity of dysregulated RTKs. Hence, targeting master regulators of RTK signaling might
alleviate this obstacle. Before that, however, defining the mechanism of such molecules is required. In this report,
we show that the Src homology phosphotyrosyl phosphatase 2 (SHP2) is a master regulator of RTK expression and
signaling in BTBC.
Methods: Xenograft tumor growth studies were used to determine the effect of SHP2 inhibition on tumorigenesis
and/or metastasis. Cell proliferation rate, anchorage-independent growth, mammosphere formation, and
ALDEFLUOR assays were used to compare the relative functional importance of SHP2 and the epidermal growth
factor receptor (EGFR) in BTBC cells. Immunohistochemistry and immunofluorescence analyses were used to
determine the state of SHP2 and EGFR coexpression in BTBC. Analysis of mitogenic and cell survival signaling was
performed to show SHP2’s role in signaling by multiple RTKs.
Results: Inhibition of SHP2 in BTBC cells suppresses their tumorigenic and metastatic properties. Because EGFR is
the most commonly dysregulated RTK in BTBC, we first tested the effect of SHP2 inhibition on EGFR signaling and
found that SHP2 is important not only for mediation of the Ras/extracellular signal-regulated kinase and the
phosphatidyl inositol 3-kinase/Akt signaling pathways but also for the expression of the receptor itself. The
existence of a tight association between SHP2 and EGFR expression in tumors and cell lines further suggested the
importance of SHP2 in EGFR expression. Comparison of relative biological significance showed the superiority of
SHP2 inhibition over that of EGFR, suggesting the existence of additional RTKs regulated by SHP2. Indeed, we found
that the expression as well as the signaling efficiency of c-Met and fibroblast growth factor receptor 1, two other
RTKs known to be dysregulated in BTBC, are SHP2-dependent. To our knowledge, this is the first demonstration of
SHP2 acting both upstream and downstream of RTKs to promote signaling.
Conclusions: SHP2 upregulates the expression and signaling of multiple RTKs to promote BTBC. These findings
provide a mechanistic explanation for the superiority of SHP2 inhibition in BTBC.
Keywords: Breast cancer, SHP2, EGFR, FGFR, c-Met
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Introduction
Of all breast cancer subtypes, basal-like and triplenegative breast cancer (BTBC) is the most aggressive
form, causing disproportionately high mortality in
women [1, 2]. The lack of targeted therapy, together
with the multiplicity of dysregulated molecules, is the
major factor that exacerbates poor clinical outcomes.
Dysregulation of multiple receptor tyrosine kinases
(RTKs), including epidermal growth factor receptor
(EGFR), fibroblast growth factor receptor 1 (FGFR1),
and hepatocyte growth factor receptor (HGFR; also
called c-Met) [3–5], is one of the major molecular
aberrations in BTBC. Of these, EGFR is the most
commonly dysregulated RTK in BTBC.
EGFR belongs to a family of RTKs that includes EGFR
itself, EGFR2, EGFR3, and EGFR4. The human counterparts are called human EGFR1–EGFR4 (or HER1–HER4).
All members are composed of an extracellular region, a
single-pass transmembrane region, and a cytoplasmic
region. With the exception of human epidermal growth
factor receptor 2 (HER2), all members are activated by
ligand binding to the extracellular domain, and all except
HER3 have a functional tyrosine kinase domain in the
cytoplasmic regions. Activation leads to homo- or heterodimerization at the cell surface and transphosphorylation
in the C-terminal tail in the cytoplasm [6–9]. Phosphorylated Tyr residues serve as binding sites for Src homology
2 (SH2) and phosphotyrosine binding domain–containing
signaling proteins [10].
Because EGFR is a potent activator of mitogenic and cell
survival signaling, its overexpression in cancer is suggested
to contribute to tumorigenesis [11], on the basis of which
anti-EGFR therapies are being sought [12, 13]. A large body
of literature shows that Src homology phosphotyrosyl phosphatase 2 (SHP2) is an essential downstream effector of
EGFR signaling [14–17]. Therefore, it is entirely possible
that dysregulated EGFR signaling in BTBC also is SHP2dependent. The upregulated expression of SHP2 in breast
cancer, including BTBC [18, 19], and its positive role in
breast cancer cell transformation [20, 21] provide supporting evidence for this possibility. SHP2 is a cytoplasmic
protein with two SH2 domains in the N terminal region
and a phosphotyrosyl phosphatase domain in the Cterminal region [15]. The PTPase function of SHP2 is activated by interaction with Tyr-phosphorylated receptors and
adaptor proteins through its SH2 domains [22, 23]. Therefore, dysregulated tyrosine kinase signaling in BTBC can
superactivate SHP2.
We recently demonstrated that SHP2 promotes the
transformation and invasive property of BTBC cells [24],
but its role on BTBC tumorigenesis in vivo was not determined. In addition, the molecular mechanism of SHP2 in
promoting BTBC is unknown. In this report, we show, for
the first time to our knowledge, that SHP2 promotes
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BTBC tumorigenesis by mediating not only downstream
RTK signaling but also receptor expression.

Materials and methods
Cells, cell cultures, and reagents

MDA-MB-231, MDA-MB-468, and MCF-10A cells were
purchased from the American Type Culture Collection
(Manassas, VA, USA), and the mouse embryonic fibroblasts (MEFs) were received from Dr. Steven Frisch
(West Virginia University). With regard to human
mammary luminal epithelial (HMLE) cells, only cell
lysates received from Dr. Alexey Ivanov (West Virginia
University) were used. The conditions for cell growth were
described previously [21, 25]. Antibodies used in the study
were anti-EGFR (610017) and anti-SHP2 (610822) from
BD Biosciences (San Jose, CA, USA); anti-CBL (sc-1651),
anti-pan-extracellular signal-regulated kinase 2 (anti-panERK2; sc81457), and anti-ubiquitin (sc271289) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); anti-β-actin
(A5441) from Sigma-Aldrich (St. Louis, MO, USA); and
anti-phospho-ERK1/2 (9101S), anti-phospho-Akt (9271S),
and anti-pan-Akt (11E7) from Cell Signaling Technology
(Danvers, MA, USA).
Silencing SHP2 and EGFR expression

We described silencing SHP2 expression in the MDAMB-231 and the MDA-MB-468 cells previously [24, 25].
For silencing EGFR, two short hairpin RNA (shRNA)
sequences described previously [26] were customsynthesized (Integrated DNA Technologies, Coralville, IA,
USA) and ligated into the lentivirus vector described for
SHP2 shRNA constructs. Lentivirus particle production
and target cell infections are described in our previous
reports [24, 25].
Induction of tumor growth by intramammary
transplantation

Female non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). Approximately 2 × 106 MDA-MB-231 or 106 MDA-MB-468 cells
expressing control or SHP2 shRNA were mixed in a 1:1
ratio with Matrigel (BD Biosciences) and injected into
the mammary fat pad of each mouse. Because shRNA-2
(sh-2) was more efficient in silencing SHP2 expression,
we used these cells for inducing tumorigenesis. We used
13 mice for the MDA-MB-231–derived cells (6 for control and 7 for shRNA) and 12 for the MDA-MB-468
cells (6 for control and 6 for shRNA) in these studies.
Tumor growth was monitored by measuring tumor
volume with a caliper. The length (L) and the width (W)
were measured directly, and the height was estimated by
calculating the average of the two measurements. Hence,
the formula L × W × (L + W)/2 was used to obtain
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tumor volume in cubic millimeters. Tumors, lungs, and
liver tissues were harvested after the mice were killed.
All experiments were performed according to the West
Virginia University Animal Care and Use Committee
guidelines.
Cell lysates, immunoblotting, and immunoprecipitation
analyses

Cell lysates were prepared in a buffer described previously [24, 25]. Preparation of samples for total cell lysate
analyses, immunoprecipitation analyses, and electrophoretic separation and immunoblotting analyses were
conducted as described previously [24, 25].
Tetramethylrhodamine -labeled EGF fluorescence studies
on dynamics of EGFR degradation

Fluorescence studies to examine the dynamics of epidermal growth factor (EGF)-induced EGFR degradation
were conducted as described previously by us and others
[27, 28]. The only additional steps in the present study
were chloroquine treatment of cells for 6 h before chilling and treatment with tetramethylrhodamine-labeled
EGF. Fluorescence images were captured using an
Olympus IX71 microscope with an attached DP30BW
digital camera and MicroSuite Basic Edition software
(Olympus America, Melville, NY, USA).
Quantitative real-time polymerase chain reaction

EGFR messenger RNA (mRNA) level was determined by
quantitative reverse transcriptase–polymerase chain
reaction (qRT-PCR) using iScript reverse transcription
Supermix and iQ SYBR Green Supermix according to
the manufacturer’s protocol (Bio-Rad Laboratories,
Hercules, CA, USA). The forward primer used was 5′CCAAAGGTCATCAACTCCCAA-3′, and the reverse
primer was 5′-AAGTGCCTATCAAGTGGATGG-3′. For
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the
forward primer used was 5′-ACAGCCTCAAGATCATCA
GCAATG-3′, and the reverse primer was 5′-TGTGGT
CATGAGTCCTTCCACGATAG-3′. The EGFR mRNA expression level was corrected against GAPDH mRNA in
both cell lines.
Immunohistochemistry

The breast tumor specimens, which were diagnosed as
BTBC at the Ruby Memorial Hospital of West Virginia
University, were obtained from the tissue bank of the
Department of Pathology, School of Medicine, West
Virginia University. The tumor samples were provided
with internal codes of the tissue bank; we did not have
any access to patient identifiers. The tumor sections
used for immunohistochemistry (IHC) were prepared
and processed using a standard protocol. The SHP2
slides were scored as described previously [19], and the
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Dako staining and visualization method (code 7298) was
used for EGFR slides (Dako, Carpinteria, CA, USA).
Immunofluorescence

Immunofluorescence (IF) of tissue sections was conducted as described previously [19]. The anti-SHP2
(sc-7384; Santa Cruz Biotechnology) and anti-EGFR
(E1157; Sigma-Aldrich) antibodies were used for IF
staining, and images were collected using an Olympus
IX71 microscope equipped with a DP30BW digital
camera and MicroSuite software.
Determining cell proliferation rate

The cell growth rate was determined by direct counting
using randomly collected microscopic pictures. Cells
were thinly seeded in 100-mm cultures dishes, and pictures were collected at a 4× lens objective in 10 random
fields immediately after attachment, and then every 24 h
thereafter for a total of 3 days. The average of cells in
fixed quadrants in each image was used for comparison
of cell proliferation rates. The growth rate was determined by dividing the averages at each time point by the
average of the initial time point.
Anchorage-independent growth assay

Cell transformation was determined by anchorageindependent growth in soft agar as described previously
[21, 29]. Colony formation was monitored by visualization
under a microscope, and pictures were taken using an
Olympus IX71 microscope equipped with a DP30BW
digital camera.
Mammosphere formation assay

We used a modified version of a previously described
protocol [30] in this study. Briefly, cells were seeded in
ultra-low attachment culture plates (approximately 5 × 105
cells per 6-cm plate) in a medium containing serum-free
Dulbecco’s modified Eagle’s medium, 1 μg/ml hydrocortisone, 10 μg/ml insulin, 10 ng/ml EGF, 10 ng/ml fibroblast
growth factor (FGF), 5 ng/ml heparin, and Gibco B-27
supplement (Life Technologies/Thermo Fisher Scientific,
Grand Island, NY, USA). After 10 days, primary mammospheres were collected by centrifugation at 1000 rpm and
dissociated to single cells by trypsination and pipetting.
Dissociated cells were recultured under the same conditions to observe the effects of SHP2 silencing on secondary mammosphere-forming efficiency. Pictures were
collected after 10 days in both cases.
ALDEFLUOR assay

The proportion of aldehyde dehydrogenase 1 (ALDH1)high cells in the control and SHP2-silenced BTBC cells
was determined using the ALDEFLUOR assay kit (catalog
number 01700; STEMCELL Technologies, Vancouver, BC,
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Canada) according to the manufacturer’s protocol. Cells
were then sorted using FACSDiva version 6.1.3 (BD
Biosciences) to determine the proportion of cells with
high ALDH1 activity.

Results
Inhibition of SHP2 in BTBC cells suppresses tumorigenesis
and metastasis

The role of SHP2 on BTBC tumorigenesis was studied
by intramammary transplantation of control and SHP2silenced BTBC cells in NOD/SCID mice. MDA-MB-231
and MDA-MB-468 cells, which are known to be basallike and triple-negative and to harbor multiple genetic
aberrations commonly discovered in BTBC [31–33],

a

were used for these studies. The expression of SHP2 was
silenced with two independent shRNAs (sh-1 and sh-2)
that were previously shown to be highly specific and
devoid of any off-target effects [24, 25, 34]. Immunoblotting data demonstrating the efficiency of SHP2 silencing
is shown in Fig. 1a. Because sh-2 showed efficient silencing, we chose these cells for in vivo studies.
Tumors induced by MDA-MB-231 cells grew very
slowly, reaching approximately 250 mm3 in the controls
and 50 mm3 in the shRNA cells within about 9 weeks
(Fig. 1b). Around this time, the control mice manifested
clinical symptoms such as shortened breathing and
reduced demeanor. These mice were killed in succession
as they developed these symptoms. However, none of

d

b
e

c

Fig. 1 In vivo tumorigenesis studies. a Analysis of Src homology phosphotyrosyl phosphatase 2 (SHP2) expression in parental (P), control (C),
shRNA-1 (sh-1), and shRNA-2 (sh-2) cells derived from MDA-MB-231 and MDA-MB-468 cells. b Tumor growth rate initiated by transplantation of
control (Con) and SHP2-silenced (sh-2) cells derived from the MDA-MB-231 cell line. Data shown are mean ± standard error of the mean of tumor
volume collected over a period of 9 weeks from six mice in each group. c Effect of SHP2 silencing on survival of mice that received transplanted
Con and sh-2 cells. d Hematoxylin and eosin (H & E)–stained mammary gland tumor sections harvested from mice that received transplanted
control and sh-2 MDA-MB-231 cells. e H & E staining of lung and liver sections harvested from mice that received transplanted control and sh-2
MDA-MB-231 cells
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the shRNA mice developed such symptoms, even by
16 weeks (Fig. 1c). These findings suggest that inhibition
of SHP2 suppresses tumorigenesis and confers survival.
Hematoxylin and eosin (H & E)–stained sections of
mammary tumors showed invasive carcinoma in the controls and connective tissue–encapsulated small tumors in
the shRNA mice (Fig. 1d). Similar analysis of lung and
liver sections showed multiple pulmonary and liver metastases in the controls and no such lesions in the shRNA
mice (Fig. 1e). These results demonstrate that silencing
SHP2 expression in the MDA-MB-231 cells suppressed
tumorigenesis and/or metastasis.
Tumors induced by the control MDA-MB-468 cells
grew relatively quickly, reaching approximately
2300 mm3 over the course of 7 weeks, but SHP2silenced tumors did not reach even 500 mm3 during
this time (Additional file 1: Figure S1a). Clinically,
tumor burden was the major issue with this cell line.
As a result, we used an average tumor size of
2000 mm3 as an endpoint to determine survival. We
found that tumors in the control mice reached this
point within 7 weeks, while none in the shRNA mice
did even by 13 weeks. Analysis of H & E–stained tissue sections showed only local invasiveness in the
mammary glands of control mice (Additional file 1:
Figure S1b and c). Regardless of this, inhibition of
SHP2 suppressed the tumorigenic property of this cell
line as well.
SHP2 promotes sustained EGFR expression and signaling
in BTBC cells

Dysregulation of EGFR in BTBC is suggested to promote
tumorigenesis [11]. Because SHP2 is a downstream effector of EGFR signaling [14, 16, 29, 35], its positive role
in BTBC could be through this mechanism. In the
present study, time course EGF stimulation studies
showed that EGF-induced Ras, ERK1/2, and Akt activation was suboptimal and short-lived in SHP2-silenced
cells but robust and sustained in controls (Fig. 2a–d).
Hence, SHP2 is essential for dysregulated EGFR signaling in BTBC cells.
Because ligand-induced receptor processing impacts signaling output, we analyzed the same total cell lysates for
EGFR to see if loss of SHP2 affects this process. Surprisingly, we found that the level of EGFR in the SHP2-silenced
cells was very low in the first place and rapidly degraded
upon EGF stimulation (Additional file 2: Figure S2a and b).
To substantiate these findings, we analyzed total cell lysates
from the parental, the control, and the two SHP2 shRNA
cells for basal EGFR levels and found a 6–8-fold reduction
in the SHP2-silenced cells (Fig. 2e and f). We also analyzed
tumor samples (Fig. 1) for EGFR protein level and ERK1/2
and Akt activation and found a drastic reduction in the
SHP2-silenced tumors (Fig. 2g). To rule out the possibility
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of shRNA-mediated artifact, we inhibited SHP2 function by
dominant-negative SHP2 expression (C459S-SHP2) and
found a 5–8-fold reduction in EGFR level when compared
with the wild-type counterpart or vector alone (Additional
file 2: Figure S2c and d). Hence, SHP2 positively regulated
EGFR expression.

SHP2 promotes elevated EGFR expression at both protein
and mRNA levels

On the basis of the data shown in Fig. 2, we reasoned
that SHP2 might act at a protein or mRNA level, or at
both levels, to promote EGFR expression. Initially, we
determined the effect of SHP2 on EGFR protein stability.
Because membrane proteins such as EGFR are degraded
primarily by the lysosomal system, we conducted lysosome inhibition studies by treating cells with 100 μg/ml
chloroquine [36] for variable times. Lysosome inhibition
led to a partial restoration of EGFR in the SHP2-silenced
cells with minimal effect in the controls (Fig. 3a and c).
Reprobing for β-actin showed comparable loading in
each lane. EGFR band density measurements confirmed
an approximately 50 % EGFR restoration within 6 h
(Fig. 3b and d). These findings suggest that SHP2 promotes stable EGFR expression in BTBC cells at least in
part by suppressing lysosomal degradation.
To corroborate the effect of SHP2 on EGFR protein
stability, we studied the dynamics of ligand-induced
EGFR degradation after stabilizing EGFR with chloroquine. Analysis of total cell lysates showed rapid EGFR
degradation in the SHP2-silenced cells and less rapid
degradation in the controls (Fig. 3e and Additional file 3:
Figure S3a). Comparison of average band densities
against the starting point in each group showed a 75 %
EGFR drop within 1 h in the SHP2-silenced cells and
only a 30 % drop within 4 h in the controls (Fig. 3f and
Additional file 3: Figure S3b). These findings suggest
that SHP2 suppresses EGFR degradation to promote elevated expression.
To confirm the immunoblotting findings, we conducted time course fluorescence studies after stabilizing
EGFR as described above (see Materials and methods).
EGF-bound EGFR was localized primarily at the plasma
membrane at the zero time point. Incubation at 37 °C
led to internalization within 10 min in both groups
(Fig. 3g and Additional file 3: Figure S3c). Further incubation led to a rapid decay in EGF-bound EGFR in the
SHP2-silenced cells, but less so in the controls. In
addition, differences in receptor distribution were observed after 10 min. While EGF-bound EGFR in the
controls was sorted in a polarized fashion (in reference
to the nucleus), it was retained in the perinuclear region
in the SHP2-silenced cells. These findings confirm the
immunoblotting data and further show that SHP2

Matalkah et al. Breast Cancer Research (2016) 18:2

a

Page 6 of 14

e

b
f

c

g
d

Fig. 2 Effect of Src homology phosphotyrosyl phosphatase 2 (SHP2) silencing on epidermal growth factor (EGF)-induced signaling. Serum-starved
control and SHP2-silenced cells were treated with EGF for variable times, and lysates prepared from them were analyzed for Ras, extracellular
signal-regulated kinases 1 and 2 (ERK1/2), and Akt activation. a Analysis of Ras activation in the MDA-MB-231 cells. b Analysis of Akt and ERK1/2
activation in the MDA-MB-231 cells. c Analysis of Ras activation in the MDA-MB-468 cells. d Analysis of Akt and ERK1/2 activation in the MDA-MB468 cells. e Analysis of epidermal growth factor receptor (EGFR) protein level in the indicated cells growing in regular (serum-containing) growth
medium. f EGFR band density measurements done using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Data presented are
mean ± standard error of the mean of at least three independent experiments. In addition, the EGFR band densities in various lanes were adjusted
using β-actin band densities. g Immunoblot analysis of tumor protein extracts for EGFR, phosphorylated ERK1/2 (pERK1/2), phosphorylated Akt
(pAkt), and SHP2. GST-RBD glutathione S-transferase-fused Ras-binding domain

suppresses ligand-induced EGFR degradation by modulating the process of sorting.
The hypersensitivity of EGFR to ligand-induced degradation in the SHP2-silenced cells was indicative of enhanced EGFR ubiquitination. We tested this possibility
after stabilizing EGFR with chloroquine and stimulating

with EGF for 2, 5, or 10 min, a time range that shows
maximal receptor ubiquitination. On one hand, EGFR was
ubiquitinated even in the basal state in the SHP2-silenced
cells, which increased upon EGF stimulation. On the other
hand, EGFR ubiquitination in the controls was undetectable in the basal state and weakly detectable after EGF
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Fig. 3 (See legend on next page.)
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(See figure on previous page.)
Fig. 3 Effect of Src homology phosphotyrosyl phosphatase 2 (SHP2) silencing on epidermal growth factor receptor (EGFR) expression. Cells were
treated with chloroquine (Chl) for variable times, washed, and then immediately stimulated with epidermal growth factor (EGF) for variable times.
Immunoblot analysis of EGFR in the control and SHP2-silenced (sh-2) MDA-MB-231 (a) and MDA-MB-468 (c) cells treated with 100 μg/ml chloroquine
for variable times. Bar graphs show EGFR band density measurements from three independent experiments in the MDA-MB-231 (b) and MDA-MB-468
(d) cells. e Dynamics of ligand-induced EGFR degradation in the presence and absence of SHP2. After chloroquine treatment, cells were stimulated
with EGF for variable times and lysates from them were analyzed for EGFR. f Bar graph shows EGFR band density measurements from three
independent experiments conducted as shown in (e). g Fluorescence images of control and short hairpin RNA (shRNA)-2 cells derived from the MDAMB-468 cells. Cells were treated with tetramethylrhodamine-labeled EGF and processed as described in Materials and methods. h Immunoblot analysis
for state of EGFR ubiquitination (Ub) in control and shRNA-2 cells after stimulation with EGF for the indicated times and immunoprecipitation with
anti-EGFR antibody (top panel). Bottom panel shows comparable EGFR protein levels in all lanes. i Quantitative reverse transcriptase–polymerase chain
reaction on EGFR mRNA levels in the control (Con) and SHP2-silenced sh-2 cells derived from the MDA-MB-231 and MDA-MB-468 cell lines. The EGFR
messenger RNA (mRNA) expression level was corrected against glyceraldehyde-3-phosphate dehydrogenase mRNA in both the control and SHP2silenced cells. The EGFR band densities in b, d, and e were adjusted using corresponding β-actin band densities

stimulation (Fig. 3h and Additional file 3: Figure S3d).
Hence, SHP2 modulated EGFR ubiquitination to promote
stability.
Because lysosome inhibition did not lead to complete
restoration of EGFR, we reasoned that SHP2 might also
promote EGFR expression at an mRNA level. qRT-PCR
analysis showed that silencing SHP2 expression led to a
9–10-fold decrease in EGFR mRNA level (Fig. 3i). These
findings show that SHP2 is important not only for EGFR
protein stability but also for mRNA expression.
SHP2 and EGFR are co-overexpressed in BTBC tumors and
cell lines

On the basis of the data shown in Figs. 2 and 3, we reasoned that both EGFR and SHP2 expression might be
dysregulated in BTBC due to stoichiometric requirements. We thus analyzed a total of 56 BTBC tumors for
EGFR and SHP2 co-overexpression by IHC and IF. In
order to include surrounding normal tissue as an internal control, the classical approach of sectioning the
whole resected tissue samples was employed.
Scores of 3+ and 2+ for each protein were considered
as positive for elevated expression. Representative pictures of EGFR and SHP2 expression in malignant and
surrounding normal tissue from two cases are shown in
Fig. 4a and Additional file 4: Figure S4a. Of the 56 tumors, 39 (approximately 70 %) and 33 (approximately
59 %) were positive for elevated SHP2 and EGFR expression, respectively (Table 1 and Additional file 6: Table
S1). Comparison of EGFR and SHP2 IHC scores in each
tumor showed a tight association in expression. We
found that 31 (94 %) of the 33 EGFR-positive tumors
were also positive for SHP2 (Additional file 6: Table S1).
Tumors positive for both proteins were further analyzed by IF microscopy to confirm co-overexpression. In
these analyses, we also paid particular attention to heterogeneous regions in each tumor. Compared with the
normal-looking regions, overexpression of EGFR and
SHP2 increased with tumor progression. Representative
IF pictures from two cases are shown in Fig. 4b and

Additional file 4: Figure S4b. These results confirm the
IHC results and further suggest that SHP2 and EGFR
are co-overexpressed in all stages of BTBC development,
with the level of expression increasing with disease
progression.
We also determined the state of EGFR and SHP2 expression in multiple BTBC cell lines (BT-20, BT-549,
MDA-MB-231, and MDA-MB-468) to confirm the IHC
and IF findings. The HER2-positive BT-474 breast cancer cell line overexpressing SHP2 [19] and the MCF-10A
cells and MEFs ectopically overexpressing HER2 and
EGFR were used as positive controls, while parental
MCF-10A cells and MEFs as well as HMLE cells were
used as negative controls for overexpression. Consistent
with the findings in BTBC tumors, EGFR and SHP2
were co-overexpressed in BTBC cells (Fig. 4c). Compared with parental MCF-10A or HMLE cells, EGFR
and SHP2 were overexpressed 4–6-fold in BTBC and experimentally produced cells (Fig. 4d). Also, the positive
control BT-474 cells had more than 7-fold SHP2. Hence,
co-overexpression of SHP2 and EGFR is commonplace.
SHP2 inhibition is superior to EGFR inhibition in
suppressing cell transformation

Because SHP2 is important for EGFR expression and
signaling, we reasoned that its positive role in BTBC
might be through this mechanism. To test this possibility, we compared the relative biological significance of
SHP2 and EGFR in BTBC cells. First, the expression of
EGFR was silenced using two shRNA constructs (Fig. 5a)
that were previously shown to be specific [26]. Next, we
compared the effect of SHP2 and EGFR silencing on cell
proliferation. While SHP2 inhibition suppressed cell proliferation by about 3–4-fold, EGFR inhibition led to only
1.5-fold suppression of cell proliferation within 3 days
(Fig. 5b and c). Thus, SHP2 inhibition is more efficient
than EGFR inhibition in suppressing cell growth.
We also compared the effect of SHP2 and EGFR silencing on anchorage-independent growth in soft
agar. On one hand while the parental and the control
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Fig. 4 Analysis of epidermal growth factor receptor (EGFR) and Src homology phosphotyrosyl phosphatase 2 (SHP2) expression in basal-like and
triple-negative breast cancer (BTBC) tumors and cell lines. a Representative 3+ immunohistochemistry (IHC) pictures of SHP2 and EGFR expression
in tumor and adjacent normal tissue. b Immunofluorescence costaining for SHP2 and EGFR showing state of expression in normal-looking, hyperplastic,
ductal carcinoma in situ (DCIS), and infiltrating ductal carcinoma (IDC) regions of a representative specimen. Note that the level of expression for both
proteins is comparable in various stages of tumor development. c Analysis of SHP2 and EGFR co-overexpression in breast cancer cell lines and in
experimentally produced EGFR-overexpressing cells. The BT-474 breast cancer cell line that overexpresses human epidermal growth factor
receptor 2 (HER2), MCF-10A, and mouse embryonic fibroblasts (MEFs) ectopically overexpressing HER2 and/or EGFR was also used in this
analysis. Parental human mammary luminal epithelial cells (HMLE), MCF-10A cells, and MEFs were used as negative controls for receptor
tyrosine kinase overexpression. d EGFR and SHP2 band density measurements from at least three independent experiments analyzed as shown
in (c). The EGFR (open bar) and SHP2 (hatched bar) band densities in the various lanes were adjusted using β-actin band densities.
DAPI 4′,6-diamidino-2-phenylindole

cells formed larger and more numerous colonies, the
SHP2-silenced cells formed smaller and fewer ones
(Fig. 5d). On the other hand, silencing EGFR led to a
modest decrease in colony number only. Viewing
under the 4× lens objective showed 22 larger colonies
per field in the controls and only 2–4 smaller
colonies in the SHP2-silenced cells (Fig. 5e and f ).
With regard to EGFR, the average colony number in

silenced cells was approximately 11 per field. These
results suggest that SHP2 plays a major role in cell
transformation, while EGFR makes a significant but
relatively modest contribution.
The inability of the SHP2-silenced cells to grow in soft
agar indicated a role for SHP2 in cancer stem cell (CSC)
biology. To verify this point, we compared the
mammosphere-forming capacity of SHP2- and EGFR-
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Table 1 Analysis of 56 basal-like and triple-negative breast cancer tumor samples
Proteins
analyzed

IHC score, n
3+

2+

1+

0

Overexpressed,
n (%)

SHP2

22

17

11

6

39 (70 %)

EGFR

13

20

9

5

33 (59 %)

EGFR epidermal growth factor receptor, IHC immunohistochemistry, SHP2 Src
homology phosphotyrosyl phosphatase 2
A total of 56 basal-like and triple-negative breast cancer tumor samples were
analyzed for SHP2 and EGFR by immunohistochemistry as described in
Materials and methods. Samples that showed 3+ and 2+ expression levels
were considered as positive for elevated expression of SHP2 and EGFR

silenced cells in suspension cultures in which cells with
stem-like properties only can survive and form these
structures [37, 38]. On one hand, whereas mammosphereforming efficiency in the parental and control cells was increased on successive passaging from primary to secondary cultures, it was exhausted in the SHP2-silenced cells
(Fig. 5g and Additional file 5: Figure S5a). On the other
hand, the impact of EGFR silencing was noticeable only in
secondary cultures, where a modest decrease in mammosphere number was observed. A further property of CSC
is increased ALDH1 activity [39] as determined using the
ALDEFLUOR assay. We used this assay to confirm the
mammosphere findings. On one while the control MDAMB-231 cells had 4.97 % ALDH1-high cells, the corresponding SHP2-silenced cells had only 0.23 %, a more

a

d

e

than 20-fold reduction (Fig. 5h). On the other hand, the
EGFR-silenced cells had 2.3 % ALDH1-high cells, suggesting a relatively modest decrease. Similar results were
obtained with the MDA-MB-468 cells (Additional file 5:
Figure S5b). Thus, SHP2 is more important than EGFR in
promoting CSC phenotypes in BTBC cells.

SHP2 promotes the expression and signaling of FGFR1
and c-Met in BTBC cells

The prominence of SHP2 inhibition over that of EGFR
in suppressing cell transformation was suggestive of
SHP2 controlling additional RTKs that are known to be
dysregulated in BTBC, such as c-Met and FGFR1 [3–5].
We thus determined the effect of SHP2 silencing on
FGFR and c-Met signaling in the same BTBC cells.
Serum-starved cells were stimulated with either FGF or
hepatocyte growth factor (HGF) for varying times, and
lysates prepared from them were analyzed for ERK1/2
and Akt activation. Both MDA-MB-231 and MDA-MB468 cells were highly responsive to stimulation with either ligand as determined by a robust activation of
ERK1/2 and Akt. While HGF- and FGF-induced ERK1/2
and Akt activation was suboptimal and short-lived in the
SHP2-silenced cells, it was augmented and sustained in
the controls (Fig. 6a–d). Hence, SHP2 regulates signaling
of multiple RTKs in BTBC cells.

g

h

b

f
c

Fig. 5 Effect of Src homology phosphotyrosyl phosphatase 2 (SHP2) and epidermal growth factor receptor (EGFR) silencing on cell proliferation,
anchorage-independent growth, and mammosphere formation. a Immunoblotting analysis of EGFR silencing with two independent short hairpin
RNA (shRNA) constructs in the MDA-MB-231 and MDA-MB-468 cells. b Effect of EGFR and SHP2 silencing on cell proliferation in MDA-MB-231 cells.
c Effect of EGFR and SHP2 silencing on cell proliferation in MDA-MB-468 cells. d Effect of EGFR and SHP2 silencing on anchorage-independent
growth in soft agar. e Colony numbers from three independent experiments in MDA-MB-231 cells cultured as shown in (d). f Colony numbers
from three independent experiments in MDA-MB-468 cells cultured as shown in (d). g Effect of EGFR and SHP2 silencing on mammosphere
formation in MDA-MB-231 cells. h Effect of EGFR and SHP2 silencing on proportion of aldehyde dehydrogenase 1 (ALDO)-high cells in MDA-MB231 cells. P parental, C control, sh-1 SHP2 shRNA-1, sh-2 SHP2 shRNA-2, Esh1 EGFR shRNA-1, Esh2 EGFR shRNA-2, SSC side scatter
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c

b

e

f
d

Fig. 6 Effect of Src homology phosphotyrosyl phosphatase 2 (SHP2) silencing on fibroblast growth factor receptor (FGFR) and c-Met expression
and signaling. a Effect of SHP2 silencing on fibroblast growth factor (FGF)-induced signaling in the MDA-MB-231 cells. b Effect of SHP2 silencing
on FGF-induced signaling in the MDA-MB-468 cells. c Effect of SHP2 silencing on hepatocyte growth factor (HGF)-induced signaling in the MDAMB-231 cells. d Effect of SHP2 silencing on HGF-induced signaling in the MDA-MB-468 cells. Note that silencing SHP2 expression led to suboptimal and short-lived FGF- or HGF-induced extracellular signal-regulated kinases 1 and 2 (ERK1/2) and Akt activation in both cell lines. e Effect of
SHP2 silencing on the protein levels of FGFR1 and c-Met in the MDA-MB-231 and MDA-MB-468 cells. f Average of band density measurements
for FGFR and c-MET from three independent experiments. Con controls, sh-1 SHP2 short hairpin RNA-1, sh-2 SHP2 short hairpin RNA-2

As described in Fig. 2, SHP2 promotes EGFR expression. We thus reasoned that SHP2 might also promote cMet and FGFR1 expression in BTBC cells. To address this
point, we analyzed the protein levels of both receptors
under basal growth conditions by immunoblotting total
cell lysates with specific antibodies. Similarly to EGFR, the
protein levels of FGFR1 and c-Met were very low in the
SHP2-silenced cells (Fig. 6e). Band density measurements
confirmed that the levels of FGFR1 and c-Met in the
SHP2-silnced cells were lower by 4–5-fold compared with
the parental and the control cells (Fig. 6f). Hence, SHP2 is
essential for the expression of FGFR and c-Met in BTBC
cells, and its inhibition leads to their downregulation.

Discussion
Dysregulation of multiple RTKs, including EGFR, FGFR1,
and HGFR (also called c-Met) [3–5], is one of the major
molecular aberrations in BTBC. As a result, efforts have
been made to develop RTK-targeting therapies to treat
BTBC. However, the results so far show that anti-RTK
drugs are ineffective when given individually and toxic

when administered in combination [3, 40]. It is therefore
imperative to discover and target master regulators of RTK
signaling to overcome this obstacle. In this report, we have
presented evidence showing that SHP2 functions as a master regulator of RTK expression and signaling in BTBC,
suggesting its potential for targeted therapy in BTBC.
Recently, we demonstrated that SHP2 promotes the
transformation and invasive properties of BTBC cells [24].
However, its role in tumorigenesis in vivo was not determined. In this report, we have demonstrated that inhibition of SHP2 effectively suppresses tumor growth
induced by intramammary transplantation of MDA-MB231 and MDA-MB-468 cells (Fig. 1b and Additional file 1:
Figure S1a). One of the most interesting observations in
mice bearing the control MDA-MB-231 tumors was the
development of clinical symptoms such as increased
breathing rate and reduced demeanor while the tumors
were still small. Silencing SHP2 expression effectively
blocked the development of these symptoms. Histopathological analysis later showed extensive lung and liver
metastatic lesions in the control mice but not in the SHP2
shRNA mice (Fig. 1d and e), validating the observed
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clinical symptoms. These findings mimic the pathogenesis
of BTBC in women in whom metastasis is often observed
while the tumors are still small. Hence, inhibition of SHP2
in BTBC may mitigate distant metastasis.
Another interesting observation was that mice bearing
SHP2-silenced MDA-MB-231 tumors survived far beyond the control group without manifesting any clinical
symptoms (Fig. 1c). Similar results were obtained with
the MDA-MB-468 cells in terms of tumor burden, which
is the major clinical manifestation with this cell line
(Additional file 1: Figure S1b). These findings imply that
inhibition of SHP2 has the potential to provide a survival benefit to BTBC patients.
Although the positive role of SHP2 in normal RTK signaling is known [14–17], its role in dysregulated RTK signaling
in cancer is unclear. In this report, we have shown that
EGFR, the most commonly dysregulated RTK in BTBC [41–
43], cannot effectively activate downstream signaling without
SHP2 (Fig. 2a–d). Unexpectedly, we discovered a new role
for SHP2: promoting elevated EGFR expression in BTBC
cells (Fig. 2e and f and Additional file 2: Figure S2a–d).
Hence, SHP2 functions not only downstream but also upstream of the EGFR.
One of the mechanisms for SHP2 in promoting elevated
EGFR expression was through blocking ubiquitination
and ligand-induced degradation (Fig. 3 and Additional file
3: Figure S3). However, our findings are in contrast to
those in a recent report that suggested otherwise on the
basis of transient expression of dominant-negative SHP2
with c-Cbl and Spry2 in COS1 cells [44]. In our studies,
expression of dominant-negative SHP2 downregulates
EGFR (Additional file 2: Figure S2c). These discrepancies
might be related to cellular context and technical differences used in the two studies. While in our studies we
used constitutive SHP2 inhibition with two different
approaches (shRNA and dominant-negative SHP2), the
researchers in the other study used transient cooverexpression. Nonetheless, our data are consistent with
SHP2 positively regulating EGFR protein stability.
The incomplete recovery of EGFR by lysosome inhibition
was an indication of the existence of additional mechanisms
used by SHP2 to promote elevated EGFR expression. Indeed, the qRT-PCR analysis showed an approximately 16fold reduction in EGFR mRNA level in SHP2-silenced
BTBC cells (Fig. 2i). These findings add more complexity
to the mechanism of SHP2 in regulating EGFR expression.
They suggest that SHP2 promotes elevated EGFR expression at both protein and mRNA levels.
The tight association of EGFR and SHP2 overexpression
in BTBC tumors (Fig. 4, Additional file 4: Figure S4 and
Table 1) and the positive role of SHP2 in EGFR expression
in BTBC cells (Figs. 2 and 3) suggest that SHP2 might also
promote EGFR overexpression in BTBC patient tumors.
Although our sample size was relatively small, the SHP2
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and EGFR results are in agreement with previously reported data [11, 18, 19, 45, 46], supporting the validity of
our data. However, the mechanism that leads to elevated
SHP2 expression and promotion of EGFR mRNA level by
SHP2 are unclear at this stage. Future studies addressing
these questions might be needed.
We have demonstrated that SHP2 plays a major role,
while EGFR makes a modest contribution, in promoting
BTBC cell proliferation, anchorage-independent growth,
and CSC phenotypes (Fig. 5 and Additional file 5: Figure
S5). The complementarity of the mammosphere and
ALDH1 findings suggests that SHP2 plays a pivotal role in
CSC survival and propagation, minority cell populations
known to perpetuate tumor growth, metastasis, and drug
resistance [37, 38]. Thus, it is entirely possible that inhibition SHP2 might lead to elimination of CSCs in tumors,
but future studies addressing this point are needed.
The superiority of SHP2 inhibition over EGFR inhibition led to the discovery that SHP2 also controls the
expression and signaling activities of FGFR1 and c-Met
(Fig. 6), two other RTKs known to be dysregulated in
BTBC. The most novel finding was that SHP2 is essential not only for downstream signaling but also for
expression of both FGFR1 and c-Met. Although our data
do not delineate between gene expression and protein
stability, we speculate that SHP2 promotes FGFR1 and
c-Met expression by acting at both protein and mRNA
levels, similar to its role in EGFR signaling. Future studies are needed to verify these points.

Conclusions
In this report, we show that inhibition of SHP2 blocks
BTBC tumorigenesis and/or metastasis. We also show that
SHP2 mediates the expression and signaling activities of
multiple RTKs, including EGFR, FGFR1, and c-Met, to promote BTBC. To our knowledge, this is the first report to
show that SHP2 acts both upstream and downstream of
RTKs to promote their oncogenic signaling. This effect of
SHP2 might be responsible for its superior role compared
with EGFR inhibition. Subsequent studies are needed to answer some of the questions raised in this report.
Additional files
Additional file 1: Figure S1. Effect of SHP2 silencing on the
tumorigenic potential of MDA-MB-468 cells. a Tumor growth rate as
determined by tumor volume measurement. b Survival plot based on
tumor size. Mice that bore tumor volume of approximately 2000 mm3 or
more were considered as not surviving and those with tumor volume
below 750 mm3 as surviving during the study period. For determining
survival, data from six control and six SH-2 mice was used. c H & E
staining of mammary tumor sections. Note that the control tumor
shows local invasiveness, while the shRNA tumor does not show any
obvious pushing front and invasiveness. d H & E staining of lung and
liver sections harvested from the control and shRNA mice that received
transplanted MDA-MB-468 cells. (PDF 695 kb)
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Additional file 2: Figure S2. Silencing SHP2 expression in the MDA-MB-231
(a) and MDA-MB-468 (b) cells drastically reduced EGFR protein level, which became hypersensitive to EGF-induced degradation. Inhibition of SHP2 by
dominant-negative (C459S-SHP2) expression led to a similar decrease (similar to
shRNA-based inhibition) in EGFR protein level, but expression of vector alone or
wild-type SHP2 (WT-SHP) did not. (a) Immunoblotting data and (b) bar graph
showing band density measurement values of the immunoblotting data. The
values represent data from at least three independent experiments. (PDF 201 kb)
Additional file 3: Figure S3. Dynamics of EGFR degradation in the
MDA-MB-231 cells in the presence and absence of SHP2. a First EGFR was
stabilized by chloroquine treatment for 6 h, and then cells were stimulated
with 10 ng/ml EGF for the indicated times. Lysates prepared from these cells
were analyzed by immunoblotting with anti-EGFR antibody. As shown, EGFR
was degraded relatively rapidly in the SHP2-silenced cells but not in the
controls. The anti-SHP2 and anti-β-actin immunoblotting show efficient
SHP2 silencing and comparable total protein loading, respectively. b Band
density measurement of the EGFR immunoblotting. As shown,
approximately 75 % of EGFR in the SHP2-silnced cells was degraded
within 1 h, but only 30 % was degraded in the controls even at the
4-h time point. Data shown are mean ± standard error of three
independent experiments. With regard to the effect of SHP2 silencing
on EGFR endocytosis and processing in the MDA-MB-231 cells, EGFinduced EGFR endocytosis was affected not by SHP2 silencing, but
by the processing thereafter. While EGFR in the controls was sorted
in polarized fashion with gradual outward extension, it remained
perinuclear in the SHP2 silenced cells. In addition, it was possible to
discern the rapid dissipation of the EGFR signal in the SHP2-silenced
cells but not in the controls. With regard to the effect of SHP2
silencing on EGFR ubiquitination in the MDA-MB-231 cells, first EGFR
was stabilized by chloroquine treatment for 6 h and then cells were
stimulated with 10 ng/ml EGF for the indicated times. Lysates
prepared from these cells were subjected to immunoprecipitation
with anti-EGFR and immunoblotting with anti-ubiquitin antibodies. To
compensate for the partial EGFR restoration by chloroquine, the
amount of EGFR precipitate loaded in the shRNA lanes was increased by
25 %. As shown, EGFR was rapidly and highly ubiquitinated in the SHP2silenced cells but less so in the controls. Reprobing with anti-EGFR antibody
showed comparable protein levels in all lanes. (PDF 310 kb)
Additional file 4: Figure S4. EGFR and SHP2 IHC staining of a BTBC
tumor. As shown, the tumor (Tum) is 3+ for both SHP2 and EGFR, while
the corresponding normal (Nor) tissue is negative for both proteins.
Immunofluorescent staining of a BTBC tumor section shows the
expression of EGFR and SHP2, which was analyzed by costaining. As
shown, the IF intensity was low in the normal region, medium in the
hyperplastic region, and higher in the ductal carcinoma in situ (DCIS) and
infiltrating ductal carcinoma (IDC) regions. (PDF 437 kb)
Additional file 5: Figure S5. a Effect of SHP2 and EGFR silencing on
primary and secondary mammosphere formation by the MDA-MB-468
cells. Note that the mammosphere-forming capacity of the SHP2-silenced
cells was exhausted in secondary passaging, while a modest reduction
was observed in the EGFR-silenced cells. b Effect of SHP2 and EGFR
silencing on proportion of ALDH1-high cells. Silencing SHP2 expression
drastically reduced the ALDH1-high cells, but silencing EGFR had only a
modest effect. (PDF 237 kb)
Additional file 6: Table S1. Internal codes for each case and the state
of EGFR and SHP2 expression for each tumor. The first 12 cases were
reanalyses of samples from a previous publication [14] in which the
indicated samples were reported as triple-negative. Cases 84–127 are
new BTBC samples. Yellow highlighting represents the co-overexpression
of SHP2 and EGFR, cyan blue represents SHP2-positive tumors that do not
have EGFR overexpression, and gray represents EGFR-positive tumors
without SHP2 overexpression. (DOC 66 kb)
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breast cancer; Chl: chloroquine; CSC: cancer stem cell; DAPI: 4′,6-diamidino-2phenylindole; DCIS: ductal carcinoma in situ; EGF: epidermal growth factor;
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